Indian Cardiovascular Market - Key trends - BRICS Research

At Rs64,189mn in 2011, cardiovascular market in India is the second largest contributor (~11%) to domestic pharmaceutical sales, and is expected to post 20% CAGR over 2011-16.

Non-communicable diseases are rapidly increasing in India, largely due to demographic and lifestyle changes. It is estimated that nearly half the disease burden in India is from non-communicable diseases, and nearly one-third of all deaths in India are due to cardiovascular diseases.

Consequently, India has huge patient pool and demand for cardiovascular drugs is high.

Cardiovascular drug market in India is highly fragmented with large number of MNC and domestic players. Sun Pharma leads the segment with nearly 7% of market share.

Ranking of top 3 players is likely to remain unchanged until the forecast period of 2016. However, companies likely to gain market share are Lupin, DRL and Ranbaxy. Of these, market share gain for Lupin is expected to be substantial leading to improved ranking for Lupin in near term.

There is unlikely to be any short term trigger that will alter dynamics of this segment in India.

In terms of various sub-segments of Indian cardiovascular market, all segments apart from anti-thrombolyics / anti-platelets would more or less remain static in growth and product offerings.

Launch of several oral anti-thrombolytics which offer significant benefits over injectable products, several landmark trials in this segment consequently leading to product approvals and expanded indications from curative to preventive thromoembolism have all contributed to trapid growth of this category of drugs.

Source : Equity Bulls

Keywords